NCT04528407 2025-02-13
BS-FU01 Follow-Up Study of FluBHPVE6E7 Study Subjects
BlueSky Immunotherapies GmbH
Completed
Clinical Trials
30 trialsNCT02653118 2024-11-12
Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)
Merck Sharp & Dohme LLC
Active not recruiting
NCT06399341 2024-05-03
PAPILOBSGR
Elpen Pharmaceutical Co. Inc.
Completed
NCT05679141 2024-04-26
Clinical Correlation Between Self-collected and Physician-collected HPV Screening Kits
Switch Health Solutions Inc.
Completed
NCT05371353 2024-04-17
Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine
Shanghai Bovax Biotechnology Co., Ltd.
Recruiting
NCT02634190 2024-02-28
Clinical Evaluation of the APTIMA® HPV Assay and Comparison With the HR HC2® Test Using LBC ThinPrep® Specimens
Hologic Deutschland GmbH
Completed
NCT06199128 2024-01-10
Fix
Uriach Consumer Healthcare
Completed
NCT01077856 2022-09-13
VIP
Merck Sharp & Dohme LLC
Completed
NCT01567813 2022-07-22
Post-Licensure Study of the Safety of GARDASIL™ in Males (V501-070)
Merck Sharp & Dohme LLC
Completed
NCT04199260 2021-08-09
PAPILOBS
Procare Health Iberia S.L.
Completed
NCT01290393 2018-07-26
Post-marketing Study to Assess the Safety of CERVARIX When Used in the United States and in Canada
GlaxoSmithKline
Terminated
NCT01101542 2018-07-23
Evaluation of Safety of a Vaccine Against Cervical Cancer in Healthy Korean Females
GlaxoSmithKline
Completed
NCT01078220 2017-07-11
Observational Surveillance Study to Detect Potential Safety Signals in Patients Who Have Had at Least One Dose of GARDASIL™ (V501-031)
Merck Sharp & Dohme LLC
Completed
NCT01062074 2017-04-17
GARDASIL Reexamination Study (V501-059)
Merck Sharp & Dohme LLC
Completed
NCT01953822 2016-12-26
Study Assessing Risk of Autoimmune Diseases in Females (9 - 25 Years) Exposed to Cervarix® in United Kingdom
GlaxoSmithKline
Completed
NCT01355003 2015-08-13
GARDASIL™ Post Marketing Surveillance in the Philippines (V501-077)
Merck Sharp & Dohme LLC
Terminated
NCT00924794 2015-04-20
Study of Natural History of Human Papillomavirus (HPV) Infections in Adult Women With Recurrent Conizations in Norway
GlaxoSmithKline
Terminated
NCT01498627 2015-04-06
PGRx
GlaxoSmithKline
Completed
NCT01187927 2015-01-26
Drug Use Investigation for Cervarix®
GlaxoSmithKline
Completed
NCT01153906 2014-12-02
Post-marketing Safety Study of Autoimmune Diseases Following Cervarix® Vaccination
GlaxoSmithKline
Completed
NCT01905462 2013-09-30
Post-marketing Safety Study to Assess the Risk of Spontaneous Abortions in Women Exposed to Cervarix Residing in UK
GlaxoSmithKline
Completed
NCT01551537 2013-09-09
Post-marketing Surveillance of GSK Biologicals' Cervarix™ When Administered to Healthy Females in Sri Lanka
GlaxoSmithKline
Withdrawn
NCT01205412 2012-11-22
An Observational Study on the Prevalence of Human Papillomavirus Types in Women in the Kingdom of Bahrain
GlaxoSmithKline
Completed
NCT01207999 2012-11-22
Type Distribution of Human Papillomavirus in Adult African Women Diagnosed With Invasive Cervical Cancer
GlaxoSmithKline
Completed
NCT01213459 2012-11-22
Study on the Prevalence of Human Papillomavirus Types in Women >= 15 Years of Age in the Kingdom of Saudi Arabia
GlaxoSmithKline
Completed
NCT01694875 2012-11-14
Clinical Evaluation of the APTIMA® HPV 16 18/45 Genotype Assay on the PANTHER® System
Gen-Probe, Incorporated
Completed
NCT01702337 2012-10-08
Prevalence-based Health and Economic Model of the Bivalent Versus the Quadrivalent Human Papillomavirus (HPV) Vaccine
GlaxoSmithKline
Completed
NCT01158209 2012-07-16
An Observational, Epidemiological Study on the Prevalence of Human Papillomavirus Types in Women in Egypt
GlaxoSmithKline
Completed
NCT01446198 2012-07-03
Clinical Evaluation of the APTIMA® HPV Assay Using the PANTHER™ System
Gen-Probe, Incorporated
Completed
NCT01384370 2011-10-06
AHPV-GT
Gen-Probe, Incorporated
Completed